RXO, Inc. (RXO) Key Metrics
RXO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.72B
- Enterprise value
- $3.99B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- 172.13
- Price / sales
- 0.8 10-yr median 0.6
- Price / book
- 2.2 10-yr median 2.7
- EV / EBITDA
- 210.1 10-yr median 32.3
- Dividend yield
- —
- Beta
- 1.99
RXO key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRXO valuation Price multiples at each fiscal year-end price.
RXO returns How much profit the business earns on the capital it uses.
RXO per-share figures Results divided by the shares outstanding at year-end.
RXO financial health Debt, liquidity and how easily interest is covered.
RXO efficiency & capital use Working capital cycle and where the cash goes.
RXO valuation history
RXO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RXO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RXO cash returned to shareholders
RXO price vs earnings per share
RXO key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $2.13B | $3.18B | $2.78B | $2.00B | — | — | — |
| Enterprise value | $2.78B | $3.81B | $3.33B | $2.52B | — | — | — |
| P/E ratio | — | — | 694.6 | 21.8 | — | — | — |
| Price / sales | 0.4 | 0.7 | 0.7 | 0.4 | — | — | — |
| Price / book | 1.4 | 2.0 | 4.7 | 3.4 | — | — | — |
| Price / free cash flow | — | — | 111.1 | 7.9 | — | — | — |
| Price / operating cash flow | 41.8 | — | 31.2 | 6.5 | — | — | — |
| EV / sales | 0.5 | 0.8 | 0.8 | 0.5 | — | — | — |
| EV / EBITDA | 77.3 | — | 32.3 | 12.1 | — | — | — |
| EV / free cash flow | — | — | 133.3 | 10.0 | — | — | — |
| Earnings yield | −4.7% | −9.1% | 0.1% | 4.6% | — | — | — |
| Free cash flow yield | −0.4% | −1.8% | 0.9% | 12.6% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.1% | 0.1% | — | — | — |
| Share price at fiscal year-end | $12.64 | $23.84 | $23.26 | $17.20 | — | — | — |
| Per share | |||||||
| Revenue per share | $34.08 | $34.10 | $32.87 | $41.20 | $40.28 | $28.84 | $26.98 |
| Earnings per share | −$0.59 | −$2.17 | $0.03 | $0.79 | $1.29 | $0.37 | $0.53 |
| Operating cash flow per share | $0.30 | −$0.09 | $0.75 | $2.66 | $1.33 | $0.21 | $1.06 |
| Free cash flow per share | −$0.05 | −$0.43 | $0.21 | $2.17 | $1.00 | −$0.19 | $0.58 |
| Cash per share | $0.10 | $0.26 | $0.04 | $0.84 | $0.25 | $0.60 | — |
| Book value per share | $9.15 | $12.08 | $4.97 | $5.04 | $9.19 | $9.18 | — |
| Tangible book value per share | −$0.14 | −$0.07 | −$0.87 | −$1.05 | $2.92 | $2.70 | — |
| Capex per share | $0.35 | $0.34 | $0.54 | $0.49 | $0.34 | $0.40 | $0.48 |
| Debt per share | $3.98 | $4.98 | $4.67 | $5.30 | $1.96 | $1.00 | — |
| Shares outstanding | 168.5M | 133.4M | 119.5M | 116.4M | 116.4M | 116.4M | 116.4M |
| Change in shares outstanding | +26.3% | +11.7% | +2.6% | 0.0% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −6.3% | −26.3% | 0.7% | 11.1% | 14.0% | 4.0% | — |
| Return on invested capital (ROIC) | −0.2% | 1.4% | 3.0% | 14.3% | 12.7% | 4.1% | — |
| Return on assets (ROA) | −3.0% | −11.1% | 0.2% | 4.5% | 7.6% | 2.3% | — |
| Return on tangible assets | −5.8% | −16.2% | 0.4% | 7.0% | 11.2% | 3.9% | — |
| Free cash flow margin | −0.1% | −1.3% | 0.6% | 5.3% | 2.5% | −0.7% | 2.1% |
| Income quality (OCF / net income) | — | — | 22.25 | 3.37 | 1.03 | 0.58 | 1.98 |
| Financial health | |||||||
| Total debt | $670.0M | $664.0M | $558.0M | $617.0M | $228.0M | $116.0M | — |
| Cash & short-term investments | $17.0M | $35.0M | $5.0M | $98.0M | $29.0M | $70.0M | — |
| Net debt | $653.0M | $629.0M | $553.0M | $519.0M | $199.0M | $46.0M | — |
| Debt / equity | 0.43 | 0.41 | 0.94 | 1.05 | 0.21 | 0.11 | — |
| Debt / assets | 0.20 | 0.19 | 0.31 | 0.30 | 0.11 | 0.06 | — |
| Net debt / EBITDA | 18.14 | — | 5.37 | 2.48 | 0.73 | 0.35 | — |
| Current ratio | 1.27 | 1.26 | 1.17 | 1.25 | 1.33 | 1.37 | — |
| Quick ratio | 1.27 | 1.26 | 1.17 | 1.25 | 1.33 | 1.37 | — |
| Interest coverage | -0.2 | 1.0 | 2.1 | 55.0 | 38.4 | 2.6 | 5.1 |
| Working capital | $279.0M | $274.0M | $114.0M | $206.0M | $267.0M | $233.0M | — |
| Invested capital | $2.19B | $2.24B | $1.15B | $1.11B | $1.27B | $1.11B | — |
| Tangible asset value | −$23.0M | −$10.0M | −$104.0M | −$122.0M | $340.0M | $314.0M | — |
| Net current asset value | −$419.0M | −$463.0M | −$435.0M | −$415.0M | $85.0M | $60.0M | — |
| Graham number | — | — | $1.94 | $9.47 | $16.33 | $8.73 | — |
| Graham net-net per share | −$4.75 | −$6.35 | −$5.60 | −$5.76 | −$1.82 | −$1.31 | — |
| Capital allocation | |||||||
| Share buybacks (net) | $1.0M | $0 | $2.0M | $3.0M | $0 | — | — |
| Dividends + buybacks / free cash flow | — | — | 8.0% | 1.2% | 0.0% | — | — |
| Capex / revenue | 1.0% | 1.0% | 1.6% | 1.2% | 0.8% | 1.4% | 1.8% |
| Capex / operating cash flow | 115.7% | — | 71.9% | 18.4% | 25.2% | 188.0% | 45.5% |
| Capex / depreciation | 0.51 | 0.52 | 0.96 | 0.66 | 0.48 | 0.62 | 0.76 |
| Stock-based compensation / revenue | 0.5% | 0.5% | 0.5% | 0.7% | 0.2% | 0.2% | 0.3% |
| SG&A / revenue | 14.5% | 14.6% | 15.0% | 1.8% | 11.5% | 14.0% | 12.7% |
| Efficiency | |||||||
| Days sales outstanding | 78.0 | 79.0 | 76.4 | 72.7 | 69.4 | 83.9 | — |
| Days payables outstanding | 41.1 | 46.5 | 51.1 | 47.3 | 42.0 | 50.5 | — |
| Cash conversion cycle (days) | 36.9 | 32.5 | 25.3 | 25.3 | 27.4 | 33.4 | — |
| Receivables turnover | 4.68 | 4.62 | 4.78 | 5.02 | 5.26 | 4.35 | — |
| Payables turnover | 8.88 | 7.85 | 7.15 | 7.71 | 8.69 | 7.23 | — |
| Asset turnover | 1.72 | 1.74 | 2.04 | 2.34 | 2.38 | 1.80 | — |
| Average receivables | $1.23B | $985.0M | $821.5M | $955.0M | $891.0M | $772.0M | — |
| Average payables | $553.5M | $491.0M | $457.5M | $510.5M | $455.0M | $390.0M | — |
| Intangibles / total assets | 47.7% | 47.5% | 38.2% | 34.9% | 35.3% | 40.3% | — |
Computed from RXO's annual financial statements (latest annual report filed February 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RXO valuation and financial ratios
RXO earned a return on equity of −6.3% and a return on invested capital of −0.2% in fiscal 2025. It ended the year with $670.0 million of debt and $17.0 million in cash and short-term investments, net debt of $653.0 million. It returned $1.0 million to shareholders: $0 in dividends and $1.0 million in share buybacks. The share count rose 44.7% from 116.4M to 168.5M over 6 years.
See the RXO income statement, the RXO chart for price history, or the RXO stock overview for the latest quote and news.
RXO key metrics FAQ
What is RXO's EV/EBITDA?
RXO's enterprise value was 77.3 times EBITDA at the end of fiscal 2025 (enterprise value $2.8 billion, EBITDA $36.0 million); the current EV/EBITDA is 210.1.
What is RXO's return on equity?
RXO's return on equity (ROE) was −6.3% in fiscal 2025: net income of -$100.0 million on average shareholders' equity of $1.6 billion.
What is RXO's ROIC?
RXO's return on invested capital was −0.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does RXO have?
RXO had total debt of $670.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.43 and $653.0 million of net debt (18.14 times EBITDA).
Does RXO buy back its shares?
Yes. RXO spent $1.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +26.3% over the year, to 168.5M..
What is RXO's free cash flow yield?
RXO generated -$8.0 million of free cash flow in fiscal 2025, a free cash flow yield of −0.4% on its market value at year-end ($2.1 billion).
What is RXO's current ratio?
RXO's current ratio was 1.27 at the end of fiscal 2025: current assets were 1.27 times current liabilities.